Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer (Q39380901)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer |
scientific article |
Statements
1 reference
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer (English)
1 reference
1 reference
Andrew J Weickhardt
1 reference
Tim J Price
1 reference
Geoff Chong
1 reference
Val Gebski
1 reference
Nick Pavlakis
1 reference
Arun Azad
1 reference
Effie Skrinos
1 reference
Kate Fluck
1 reference
Renato Salemi
1 reference
Niall C Tebbutt
1 reference
12 March 2012
1 reference
1 reference
30
1 reference
13
1 reference
1505-1512
1 reference
Identifiers
1 reference
1 reference